title: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.
authors.forename: A C
authors.initials: AC
authors.lastname: Schoolwerth
authors.forename: D A
authors.initials: DA
authors.lastname: Sica
authors.forename: B J
authors.initials: BJ
authors.lastname: Ballermann
authors.forename: C S
authors.initials: CS
authors.lastname: Wilcox
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D000572:American Heart Association; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D000075202:Contraindications; D019468:Disease Management; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006947:Hyperkalemia / Q000209:etiology / Q000628:therapy; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects*; D010953:Plasma Volume; D006435:Renal Dialysis; D012307:Risk Factors; D013903:Thoracic Surgery
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors